Gregory Davis, PhD, Vice President of Genome Engineering at Sangamo Therapeutics, gives an overview of zinc finger proteins which play a crucial part in Sangamo’s proprietary zinc finger platform.
As Dr. Davis explains, zinc finger proteins are naturally occurring human DNA-binding proteins and may be engineered to specifically bind any genomic sequence. When fused to transcriptional regulatory domains to form zinc finger protein transcription factors, they can be used to modulate the expression level of the targeted gene. This gives this technology the potential to target a variety of diseases caused by single-gene diseases.
To stay abreast with the latest news in rare disease, sign up for one of our newsletters.